Bridge Biotherapeutics, Inc. (KOSDAQ:288330)
South Korea
· Delayed Price · Currency is KRW 742.00
+7.00 (0.95%)
At close: May 28, 2025, 3:30 PM KST
Bridge Biotherapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Revenue | 11.18 | 2.18 | 100 | 3,024 | 1,924 | 6,340 | Upgrade
|
| Revenue Growth (YoY) | -88.82% | -97.82% | -96.69% | 57.15% | -69.65% | -89.12% | Upgrade
|
| Cost of Revenue | 19.66 | 14.59 | 16.27 | 179.53 | 11.09 | 7,464 | Upgrade
|
| Gross Profit | -8.48 | -12.41 | 83.73 | 2,844 | 1,913 | -1,124 | Upgrade
|
| Selling, General & Admin | 7,721 | 8,560 | 13,543 | 13,033 | 10,304 | 5,649 | Upgrade
|
| Research & Development | 9,205 | 8,825 | 25,299 | 32,093 | 17,517 | 12,373 | Upgrade
|
| Other Operating Expenses | 140.07 | 179.16 | 166.06 | 141.42 | 101.68 | 74.05 | Upgrade
|
| Operating Expenses | 18,485 | 18,996 | 40,433 | 46,346 | 28,305 | 18,454 | Upgrade
|
| Operating Income | -18,494 | -19,008 | -40,349 | -43,501 | -26,392 | -19,578 | Upgrade
|
| Interest Expense | -188.83 | -188.83 | -170.65 | -64.75 | -7.53 | -6.34 | Upgrade
|
| Interest & Investment Income | 421.39 | 421.39 | 1,034 | 950.97 | 350.68 | 208.73 | Upgrade
|
| Currency Exchange Gain (Loss) | -119.57 | -119.57 | 140.18 | -203.79 | 65.9 | 107.46 | Upgrade
|
| Other Non Operating Income (Expenses) | 28.84 | -0.86 | -2,181 | 1,068 | -295.88 | -149.94 | Upgrade
|
| EBT Excluding Unusual Items | -18,352 | -18,896 | -41,527 | -41,751 | -26,279 | -19,418 | Upgrade
|
| Gain (Loss) on Sale of Investments | -492.61 | -492.61 | -928.7 | 51.29 | 0.3 | 186.87 | Upgrade
|
| Gain (Loss) on Sale of Assets | -22.97 | -22.97 | - | - | - | -1.05 | Upgrade
|
| Asset Writedown | -521.15 | -521.15 | - | - | - | - | Upgrade
|
| Pretax Income | -19,388 | -19,933 | -42,455 | -41,700 | -26,278 | -19,232 | Upgrade
|
| Earnings From Continuing Operations | -19,388 | -19,933 | -42,455 | -41,700 | -26,278 | -19,232 | Upgrade
|
| Minority Interest in Earnings | 119.74 | 177.21 | 134.36 | - | - | - | Upgrade
|
| Net Income | -19,269 | -19,756 | -42,321 | -41,700 | -26,278 | -19,232 | Upgrade
|
| Net Income to Common | -19,269 | -19,756 | -42,321 | -41,700 | -26,278 | -19,232 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 41 | 30 | 24 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 41 | 30 | 24 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | 38.11% | 35.66% | 26.02% | 1.56% | 2.53% | 96.53% | Upgrade
|
| EPS (Basic) | -428.96 | -485.40 | -1410.65 | -1751.63 | -1121.11 | -841.28 | Upgrade
|
| EPS (Diluted) | -428.96 | -485.40 | -1411.00 | -1751.67 | -1121.11 | -841.67 | Upgrade
|
| Free Cash Flow | -17,092 | -20,716 | -32,095 | -40,619 | -21,293 | -13,117 | Upgrade
|
| Free Cash Flow Per Share | -380.51 | -509.00 | -1069.79 | -1706.25 | -908.42 | -573.78 | Upgrade
|
| Gross Margin | -75.86% | - | 83.73% | 94.06% | 99.42% | -17.73% | Upgrade
|
| Operating Margin | -165444.76% | -872715.86% | -40349.29% | -1438.66% | -1371.60% | -308.81% | Upgrade
|
| Profit Margin | -172379.42% | -907030.64% | -42320.90% | -1379.08% | -1365.70% | -303.35% | Upgrade
|
| Free Cash Flow Margin | -152909.49% | -951137.57% | -32094.94% | -1343.35% | -1106.61% | -206.90% | Upgrade
|
| EBITDA | -17,074 | -17,577 | -38,925 | -42,423 | -26,010 | -19,220 | Upgrade
|
| D&A For EBITDA | 1,419 | 1,432 | 1,424 | 1,078 | 381.46 | 357.87 | Upgrade
|
| EBIT | -18,494 | -19,008 | -40,349 | -43,501 | -26,392 | -19,578 | Upgrade
|
| Advertising Expenses | - | 4.98 | 31.39 | 28.01 | 10.95 | 29.98 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.